Stephen Liu, MD, on Key Takeaways From the ARROW Trial of Pralsetinib for RET+ NSCLC

Video

At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.

CancerNetwork® sat down with Stephen Liu, MD, of the Georgetown Lombardi Comprehensive Cancer Center, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about how results of the ARROW trial (NCT02412878), which looked at pralsetinib (Gavreto) as therapy for patients with RET fusion–positive non–small cell lung cancer (NSCLC) in the frontline, influence the need to select patients for targeted therapy. He emphasized that delivering treatment effectively involves uncovering oncogenic drivers of the disease, such as genetic mutations.

Transcription:

I think that the key takeaway from this study is that we can see extremely effective [drugs with] overwhelmingly positive results when we deliver treatment to the right patients. If we give this drug to an all-comer population, response will be quite low. Whereas if we can rationally select and identify these patients a priori and deliver treatment [where] it makes sense, we can see these outcomes where almost everyone has a response [and] where responses are very durable and toxicity is minimal. It really is a matter of delivering this treatment where it’s needed. That rational drug development has been the paradigm for the past few years in lung cancer. It extends to the resistance setting as well where past initial diagnosis, if we can apply that same paradigm post initial progression, we can deliver drugs that can overcome acquired resistance in the future as well.

Reference

Curigliano G, Gainor JF, Greisinger F, et al. Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. J Clin Oncol. 2021;39(suppl 15):9089. doi:10.1200/JCO.2021.39.15_suppl.9089

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
4 experts in this video
4 experts in this video
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content